• Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

News & Events

Syngene purchases land to expand operations in Genome Valley, Hyderabad
14th Sep, 2023
Q1 FY24 revenue up 26%, PAT up 26%
25th Jul, 2023
Panbela announces issuance of new patent in Australia. Patent is for claims of a novel process for the production of SBP-101
15th Jul, 2023
Syngene to acquire multi-model facility from Stelis Biopharma Ltd
2nd Jul, 2023
Sustained positive performance in fourth quarter delivers strong full year results
24th Apr, 2023
Syngene reports strong third quarter results
23rd Jan, 2023
Syngene and the Research and Innovation Circle of Hyderabad (RICH) launch scholarship program for women studying STEM subjects
9th Nov, 2022
Syngene reports second quarter results Revenue from operations up 26% to Rs. 768 crores, PAT increased 11% to Rs.102 crores
19th Oct, 2022
Syngene reports revenue from operations up 8% in the first quarter
20th Jul, 2022
Syngene signs 10-year biologics manufacturing agreement with leading animal health company, Zoetis
14th Jul, 2022
Syngene reports full year revenue from operations up 19% to Rs. 2604 Cr
27th Apr, 2022
Syngene International takes top honors at CMO Leadership Awards 2022 for contract manufacturing
9th Mar, 2022
Syngene releases its first ESG report for FY2020-21 in accordance with the Global Reporting Initiative (GRI)
24th Feb, 2022
Syngene reports 10% growth in revenue from operations to Rs.6,414 Mn and raises full-year guidance
19th Jan, 2022
Syngene International Announces Extension of Collaboration with Amgen
16th Dec, 2021
Syngene through Biocon Foundation partners with NIMHANS for BHUMI
10th Dec, 2021
Syngene reports second quarter results Revenue from operations up 17% to Rs. 6,102 Mn, PAT increased 9% to Rs. 920 Mn
20th Oct, 2021
Syngene expands biopharma-manufacturing capacity. Sets up a state-of-the-art microbial facility; expands mammalian facility
12th Aug, 2021
Syngene announces senior-level appointments Strengthens leadership in USA
4th Aug, 2021
Syngene reports first quarter results Revenue from operations up 41% to Rs. 5,945 Mn, PAT increased 33% to Rs. 773 Mn
20th Jul, 2021

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To view or email, Please share your details view

To download, Please share your details